Zobrazeno 1 - 9
of 9
pro vyhledávání: '"John C, Gutheil"'
Autor:
Charles L, Vogel, Melody A, Cobleigh, Debu, Tripathy, John C, Gutheil, Lyndsay N, Harris, Louis, Fehrenbacher, Dennis J, Slamon, Maureen, Murphy, William F, Novotny, Michael, Burchmore, Steven, Shak, Stanford J, Stewart, Michael, Press
Publikováno v:
Journal of Clinical Oncology. 41:1638-1645
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS One hundred fourteen women with HER2-overexpressing metastatic breast cancer were ran
Autor:
Marina Konopleva, Peter F. Thall, Cecilia Arana Yi, Gautam Borthakur, Andrew Coveler, Carlos Bueso-Ramos, Juliana Benito, Sergej Konoplev, Yongchuan Gu, Farhad Ravandi, Elias Jabbour, Stefan Faderl, Deborah Thomas, Jorge Cortes, Tapan Kadia, Steven Kornblau, Naval Daver, Naveen Pemmaraju, Hoang Q. Nguyen, Jennie Feliu, Hongbo Lu, Caimiao Wei, William R. Wilson, Teresa J. Melink, John C. Gutheil, Michael Andreeff, Elihu H. Estey, Hagop Kantarjian
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-1
Externí odkaz:
https://doaj.org/article/9b9128ff96344fda8aed35d1dfe2946a
Publikováno v:
Journal of Clinical Oncology. 20:937-940
PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. PATIENTS AND METHODS: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for ad
Autor:
John C. Gutheil
Publikováno v:
Current Oncology Reports. 2:582-586
The treatment of breast cancer has benefited substantially from the introduction of trastuzumab in 1998. Yet trastuzumab only represents the first of a series of newer biologic therapies that will change the manner in which patients with breast cance
Publikováno v:
Journal of Chromatography B: Biomedical Sciences and Applications. 655:147-152
In this paper we present a new HPLC method for the determination of novobiocin in human serum. The assay uses mitomycin C as an internal standard, protein precipitation with acetonitrile, an ODS reversed-phase column with an isocratic mobile phase of
Autor:
Eugene F. Cimino, Samuel W. Needleman, Vikram Kapil, John C. Gutheil, Gursharan Chana, Shrikant M. Mane
Publikováno v:
Pathology. 22:77-81
Activation of ras protooncogenes by any of several possible mutations in codons 12, 13 or 61 has been demonstrated in a variety of human malignancies, including acute non-lymphoblastic leukemia (ANLL). In situ staining for the ras gene product, p21,
Autor:
Kurt A, Jaeckle, Tracy, Batchelor, Steven J, O'Day, Surasak, Phuphanich, Pamela, New, Glenn, Lesser, Allen, Cohn, Mark, Gilbert, Robert, Aiken, Deborah, Heros, Lisa, Rogers, Eric, Wong, Dorcas, Fulton, John C, Gutheil, Said, Baidas, Julia M, Kennedy, Warren, Mason, Paul, Moots, Christy, Russell, Lode J, Swinnen, Stephen B, Howell
Publikováno v:
Journal of neuro-oncology. 57(3)
Drugs currently available for intrathecal administration are cleared rapidly from the CSF. DepoCyt is a slow-release formulation of cytarabine that maintains cytotoxic concentrations of free cytarabine in the CSF for14 days following a single injecti
Publikováno v:
Genes, chromosomescancer. 2(1)
RAS protooncogene activation has been repeatedly demonstrated in neoplastic cell DNA from patients with AML. Despite the convincing demonstration that activating RAS gene point mutations are critical in model systems, their precise prevalence and imp
Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21
Publikováno v:
Human pathology. 20(12)
In the process of developing accurate quantitation of the ras protein (p21), we have screened available anti- ras antibodies for their utility in immunoprecipitation. Immunoprecipitation with the anti- ras antibody RAP-5 consistently failed to precip